Literature DB >> 35633272

Misuse of Antipyretic Amid Fear of COVID-19 Vaccine.

Arun Gautam1, Urza Bhattarai2.   

Abstract

The COVID-19 vaccination campaign is going on in Nepal through different phases of immunisation. It has been observed that people are misusing antipyretics and analgesics with the fear of adverse events following immunisation. The possibility of antipyretics and analgesics blunting the antibody response of the human body can be a potential cause for lower immune response and thus a reason for lower efficacy of the vaccine. Prophylactic use of over-the-counter analgesics and antipyretics is to be discouraged until the data for or against its use is available. Keywords: antipyretics; COVID-19 vaccine; drug misuse; vaccine immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35633272      PMCID: PMC9226747          DOI: 10.31729/jnma.6262

Source DB:  PubMed          Journal:  JNMA J Nepal Med Assoc        ISSN: 0028-2715            Impact factor:   0.556


  4 in total

Review 1.  The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review.

Authors:  Rashmi Ranjan Das; Inusha Panigrahi; Sushree Samiksha Naik
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

2.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Authors:  Pedro M Folegatti; Katie J Ewer; Parvinder K Aley; Brian Angus; Stephan Becker; Sandra Belij-Rammerstorfer; Duncan Bellamy; Sagida Bibi; Mustapha Bittaye; Elizabeth A Clutterbuck; Christina Dold; Saul N Faust; Adam Finn; Amy L Flaxman; Bassam Hallis; Paul Heath; Daniel Jenkin; Rajeka Lazarus; Rebecca Makinson; Angela M Minassian; Katrina M Pollock; Maheshi Ramasamy; Hannah Robinson; Matthew Snape; Richard Tarrant; Merryn Voysey; Catherine Green; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Andrew J Pollard
Journal:  Lancet       Date:  2020-07-20       Impact factor: 79.321

3.  Oxford-AstraZeneca COVID-19 vaccine efficacy.

Authors:  Maria Deloria Knoll; Chizoba Wonodi
Journal:  Lancet       Date:  2020-12-08       Impact factor: 79.321

4.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Authors:  Maheshi N Ramasamy; Angela M Minassian; Katie J Ewer; Amy L Flaxman; Pedro M Folegatti; Daniel R Owens; Merryn Voysey; Parvinder K Aley; Brian Angus; Gavin Babbage; Sandra Belij-Rammerstorfer; Lisa Berry; Sagida Bibi; Mustapha Bittaye; Katrina Cathie; Harry Chappell; Sue Charlton; Paola Cicconi; Elizabeth A Clutterbuck; Rachel Colin-Jones; Christina Dold; Katherine R W Emary; Sofiya Fedosyuk; Michelle Fuskova; Diane Gbesemete; Catherine Green; Bassam Hallis; Mimi M Hou; Daniel Jenkin; Carina C D Joe; Elizabeth J Kelly; Simon Kerridge; Alison M Lawrie; Alice Lelliott; May N Lwin; Rebecca Makinson; Natalie G Marchevsky; Yama Mujadidi; Alasdair P S Munro; Mihaela Pacurar; Emma Plested; Jade Rand; Thomas Rawlinson; Sarah Rhead; Hannah Robinson; Adam J Ritchie; Amy L Ross-Russell; Stephen Saich; Nisha Singh; Catherine C Smith; Matthew D Snape; Rinn Song; Richard Tarrant; Yrene Themistocleous; Kelly M Thomas; Tonya L Villafana; Sarah C Warren; Marion E E Watson; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Saul N Faust; Andrew J Pollard
Journal:  Lancet       Date:  2020-11-19       Impact factor: 79.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.